MX383034B - Tratamiento de cáncer de pulmón con inhibidores de glutaminasa. - Google Patents
Tratamiento de cáncer de pulmón con inhibidores de glutaminasa.Info
- Publication number
- MX383034B MX383034B MX2017012824A MX2017012824A MX383034B MX 383034 B MX383034 B MX 383034B MX 2017012824 A MX2017012824 A MX 2017012824A MX 2017012824 A MX2017012824 A MX 2017012824A MX 383034 B MX383034 B MX 383034B
- Authority
- MX
- Mexico
- Prior art keywords
- lung cancer
- glutaminase inhibitors
- cancer treatment
- glutaminase
- inhibitors
- Prior art date
Links
- 102000009127 Glutaminase Human genes 0.000 title abstract 3
- 108010073324 Glutaminase Proteins 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 208000020816 lung neoplasm Diseases 0.000 title abstract 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 title abstract 2
- 201000005202 lung cancer Diseases 0.000 title abstract 2
- 206010069755 K-ras gene mutation Diseases 0.000 abstract 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562143494P | 2015-04-06 | 2015-04-06 | |
| US201562149489P | 2015-04-17 | 2015-04-17 | |
| PCT/US2016/026127 WO2016164401A1 (en) | 2015-04-06 | 2016-04-06 | Treatment of lung cancer with inhibitors of glutaminase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017012824A MX2017012824A (es) | 2018-05-15 |
| MX383034B true MX383034B (es) | 2025-03-13 |
Family
ID=57015711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017012824A MX383034B (es) | 2015-04-06 | 2016-04-06 | Tratamiento de cáncer de pulmón con inhibidores de glutaminasa. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10441587B2 (enExample) |
| EP (1) | EP3280415A4 (enExample) |
| JP (2) | JP6944377B2 (enExample) |
| KR (1) | KR20170132333A (enExample) |
| CN (1) | CN107949387B (enExample) |
| AU (1) | AU2016246521B2 (enExample) |
| BR (1) | BR112017021312A2 (enExample) |
| CA (1) | CA2981762A1 (enExample) |
| EA (1) | EA035354B1 (enExample) |
| IL (1) | IL254876A0 (enExample) |
| MX (1) | MX383034B (enExample) |
| SG (1) | SG11201708153XA (enExample) |
| WO (1) | WO2016164401A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8604016B2 (en) | 2011-11-21 | 2013-12-10 | Calithera Biosciences Inc. | Heterocyclic inhibitors of glutaminase |
| HUE056078T2 (hu) | 2012-11-16 | 2022-01-28 | Calithera Biosciences Inc | Heterociklusos glutamináz inhibitorok |
| HRP20192056T1 (hr) | 2014-04-30 | 2020-02-21 | Pfizer Inc. | Derivati diheterocikla vezani na cikloalkil |
| JP6889101B2 (ja) | 2014-08-07 | 2021-06-18 | キャリセラ バイオサイエンシーズ， インコーポレイテッド | グルタミナーゼ阻害剤の結晶形態 |
| SG11201802830QA (en) | 2015-10-05 | 2018-05-30 | Calithera Biosciences Inc | Combination therapy with glutaminase inhibitors and immuno-oncology agents |
| WO2018039544A1 (en) | 2016-08-25 | 2018-03-01 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors |
| WO2018039441A1 (en) | 2016-08-25 | 2018-03-01 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors |
| AU2018231058A1 (en) * | 2017-03-10 | 2019-09-19 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors |
| JP7188936B2 (ja) * | 2018-08-21 | 2022-12-13 | 国立大学法人富山大学 | 抗炎症剤 |
| JP7156856B2 (ja) * | 2018-08-21 | 2022-10-19 | 国立大学法人富山大学 | 抗肥満剤 |
| WO2021076814A1 (en) * | 2019-10-15 | 2021-04-22 | Cornell University | Methods of inhibiting liver-type glutaminase, gls2 |
| US12653785B2 (en) * | 2020-05-21 | 2026-06-16 | University of Pittsburgh—of the Commonwealth System of Higher Education | Compositions and methods for administering a YAP1/WWRT1 inhibiting composition and a GLS1 inhibiting composition |
| CN111514460B (zh) * | 2020-05-22 | 2021-12-14 | 西安交通大学 | 大气压冷等离子体在抑制谷氨酰胺酶活性方面的用途及酶抑制剂 |
| CN113956233B (zh) * | 2021-10-22 | 2023-06-06 | 南方医科大学 | 一种酰胺类化合物或其药学上可接受的盐及其制备方法和应用 |
| US20250288577A1 (en) * | 2022-04-29 | 2025-09-18 | Cornell University | Methods of treating a virus infection and methods of inhibiting viral replication |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1019519A (en) | 1911-07-11 | 1912-03-05 | Oscar Martin Polin | Apparatus for making backing for teeth. |
| US6451828B1 (en) | 2000-08-10 | 2002-09-17 | Elan Pharmaceuticals, Inc. | Selective inhibition of glutaminase by bis-thiadiazoles |
| AU2002305926A1 (en) | 2001-02-05 | 2002-10-08 | Exegenics Inc. | Cysteine protease inhibitors |
| WO2005113798A2 (en) | 2004-04-15 | 2005-12-01 | University Of Florida Research Foundation, Inc. | Proteolytic markers as diagnostic biomarkers for cancer, organ injury and muscle rehabilitation/exercise overtraining |
| TWI478709B (zh) | 2008-02-19 | 2015-04-01 | Earnest Medicine Co Ltd | A useful oral or enteral composition for the recovery of bodily functions |
| US20130109643A1 (en) | 2010-05-10 | 2013-05-02 | The Johns Hopkins University | Metabolic inhibitor against tumors having an idh mutation |
| US10064885B2 (en) | 2010-07-09 | 2018-09-04 | Massachusetts Institute Of Technology | Metabolic gene, enzyme, and flux targets for cancer therapy |
| WO2012068512A1 (en) | 2010-11-18 | 2012-05-24 | Deuteria Pharmaceuticals Llc | 3-deutero-pomalidomide |
| CN103030597B (zh) * | 2011-09-30 | 2014-10-01 | 南昌滨西科技有限公司 | 肾脏型谷氨酰胺酶抑制剂及其制备方法和用途 |
| CN108785305B (zh) * | 2011-11-21 | 2021-10-29 | 卡利泰拉生物科技公司 | 谷氨酰胺酶的杂环抑制剂 |
| US8604016B2 (en) | 2011-11-21 | 2013-12-10 | Calithera Biosciences Inc. | Heterocyclic inhibitors of glutaminase |
| AU2013266243A1 (en) * | 2012-05-24 | 2014-12-18 | Beth Israel Deaconess Medical Center, Inc. | Targeting the glutamine to pyruvate pathway for treatment of oncogenic Kras-associated cancer |
| CN104797256A (zh) | 2012-09-10 | 2015-07-22 | 细胞基因公司 | 用于治疗局部晚期乳腺癌的方法 |
| EP2895623B1 (en) | 2012-09-17 | 2018-08-22 | Agios Pharmaceuticals, Inc. | Use of e-cadherin and vimentin for selection of treatment responsive patients |
| HUE056078T2 (hu) | 2012-11-16 | 2022-01-28 | Calithera Biosciences Inc | Heterociklusos glutamináz inhibitorok |
| SG11201504022RA (en) | 2012-11-21 | 2015-06-29 | Agios Pharmaceuticals Inc | Glutamase inhibitors and method of use |
| WO2014079011A1 (en) | 2012-11-22 | 2014-05-30 | Agios Pharmaceuticals, Inc. | Heterocyclic compounds for inhibiting glutaminase and their methods of use |
| HK1220640A1 (zh) * | 2012-12-03 | 2017-05-12 | Calithera Biosciences, Inc. | 用谷氨醯胺酶的杂环抑制剂治疗癌症 |
| WO2015061432A1 (en) | 2013-10-25 | 2015-04-30 | Calithera Biosciences, Inc. | Treatment of viral infections with inhibitors of glutaminase |
| WO2015138902A1 (en) | 2014-03-14 | 2015-09-17 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors |
| US10221459B2 (en) | 2014-05-13 | 2019-03-05 | Case Western Reserve University | Compositions and methods of treating cancer harboring PIKC3A mutations |
| SG11201610333VA (en) | 2014-06-13 | 2017-01-27 | Calithera Biosciences Inc | Combination therapy with glutaminase inhibitors |
| WO2016004418A1 (en) | 2014-07-03 | 2016-01-07 | Board Of Regents, University Of Texas System | Glutaminase inhibitor therapy |
| WO2016014890A1 (en) | 2014-07-24 | 2016-01-28 | Calithera Biosciences, Inc. | Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase |
| JP6889101B2 (ja) | 2014-08-07 | 2021-06-18 | キャリセラ バイオサイエンシーズ， インコーポレイテッド | グルタミナーゼ阻害剤の結晶形態 |
| WO2016054388A1 (en) | 2014-10-03 | 2016-04-07 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Glutaminase inhibitors |
| US10517844B2 (en) | 2014-11-13 | 2019-12-31 | Buck Institute For Research On Aging | Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications |
| JP6768693B2 (ja) * | 2015-03-30 | 2020-10-14 | キャリセラ バイオサイエンシーズ， インコーポレイテッド | グルタミナーゼ阻害剤を投与する方法 |
| WO2018039441A1 (en) | 2016-08-25 | 2018-03-01 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors |
| US20180055825A1 (en) | 2016-08-25 | 2018-03-01 | Yu Liang | Treatment of cancer with inhibitors of glutaminase |
| WO2018039544A1 (en) | 2016-08-25 | 2018-03-01 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors |
-
2016
- 2016-04-06 BR BR112017021312A patent/BR112017021312A2/pt not_active IP Right Cessation
- 2016-04-06 WO PCT/US2016/026127 patent/WO2016164401A1/en not_active Ceased
- 2016-04-06 KR KR1020177032006A patent/KR20170132333A/ko not_active Ceased
- 2016-04-06 SG SG11201708153XA patent/SG11201708153XA/en unknown
- 2016-04-06 EP EP16777159.1A patent/EP3280415A4/en not_active Withdrawn
- 2016-04-06 AU AU2016246521A patent/AU2016246521B2/en not_active Ceased
- 2016-04-06 MX MX2017012824A patent/MX383034B/es unknown
- 2016-04-06 EA EA201792227A patent/EA035354B1/ru not_active IP Right Cessation
- 2016-04-06 CN CN201680032522.7A patent/CN107949387B/zh not_active Expired - Fee Related
- 2016-04-06 JP JP2017552153A patent/JP6944377B2/ja not_active Expired - Fee Related
- 2016-04-06 CA CA2981762A patent/CA2981762A1/en not_active Abandoned
- 2016-04-06 US US15/091,816 patent/US10441587B2/en not_active Expired - Fee Related
-
2017
- 2017-10-03 IL IL254876A patent/IL254876A0/en unknown
-
2021
- 2021-04-16 JP JP2021069815A patent/JP2021102662A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP3280415A1 (en) | 2018-02-14 |
| JP6944377B2 (ja) | 2021-10-06 |
| JP2021102662A (ja) | 2021-07-15 |
| EA201792227A1 (ru) | 2018-11-30 |
| CN107949387A (zh) | 2018-04-20 |
| AU2016246521A8 (en) | 2019-08-15 |
| IL254876A0 (en) | 2017-12-31 |
| EP3280415A4 (en) | 2018-12-26 |
| JP2018510884A (ja) | 2018-04-19 |
| WO2016164401A8 (en) | 2017-11-23 |
| MX2017012824A (es) | 2018-05-15 |
| AU2016246521A1 (en) | 2017-11-02 |
| KR20170132333A (ko) | 2017-12-01 |
| WO2016164401A1 (en) | 2016-10-13 |
| US20160287585A1 (en) | 2016-10-06 |
| CA2981762A1 (en) | 2016-10-13 |
| BR112017021312A2 (pt) | 2018-06-26 |
| AU2016246521B2 (en) | 2020-07-09 |
| SG11201708153XA (en) | 2017-11-29 |
| US10441587B2 (en) | 2019-10-15 |
| CN107949387B (zh) | 2021-08-13 |
| EA035354B1 (ru) | 2020-06-01 |
| HK1254349A1 (zh) | 2019-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017012824A (es) | Tratamiento de cáncer de pulmón con inhibidores de glutaminasa. | |
| EA201990296A1 (ru) | Антитела против siglec-7 для лечения рака | |
| MX392368B (es) | Composiciones y metodos para el tratamiento del cancer | |
| EA201992781A1 (ru) | Ингибиторы g12c kras и способы их применения | |
| EA201992251A1 (ru) | Противораковые вакцины и способы лечения с их применением | |
| PH12019500668A1 (en) | Anti-lag-3 antibodies and compositions | |
| TW201611847A (en) | Compounds and compositions for treating EGFR expressing tumors | |
| MX2018003936A (es) | Anticuerpos anti proteina de muerte celular programada 1 (pd-1) y composiciones. | |
| MX2018008426A (es) | Combinaciones anti-egfr para tratar tumores. | |
| MX2020006297A (es) | Variantes de cd19. | |
| EP4691562A3 (en) | Anti-pd-l1 combinations for treating tumors | |
| EA201790802A1 (ru) | Соединения против tnf | |
| EA201891340A1 (ru) | Лечение рака с использованием 2-дезокси-2-фтор-l-фукозы в комбинации с ингибитором контрольных точек | |
| MX2018008427A (es) | Combinaciones anti-cd20 para tratar tumores. | |
| MX379621B (es) | Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer | |
| MX2018000715A (es) | Metodos para tratar cancer usando apilimod. | |
| MX382996B (es) | Inhibidores de pcna | |
| MX2017006026A (es) | Apilimod para uso en el tratamiento de cancer colorrectal. | |
| EA201890884A1 (ru) | Способ и композиции для нежелательных и аномальных мышечных сокращений | |
| MX379271B (es) | Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cáncer. | |
| TW201613587A (en) | Medical treatments based on anamorelin | |
| MX390320B (es) | Farmaco de combinacion. | |
| PH12018501455A1 (en) | Therapeutic compostions and methods for treating hepatitis b | |
| MX2019008233A (es) | Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral. | |
| GB2569488A (en) | PD-1 specific aptamers |